Balaji V Kadri

Title: The Innovations of Balaji V Kadri

Introduction

Balaji V Kadri is an accomplished inventor based in Tampa, FL (US). He has made significant contributions to the field of pharmaceuticals, particularly in the development of sustained release oral dosage forms. With a total of 3 patents to his name, Kadri's work has the potential to impact the treatment of various diseases and disorders.

Latest Patents

Kadri's latest patents include innovative formulations for GABA analog prodrug sustained release oral dosage forms. One of his notable inventions is the sustained release oral dosage form of a gabapentin prodrug, specifically 1-{[(α-isobutanoyloxyethoxy)carbonyl]aminomethyl}-1-cyclohexane acetic acid. These dosage forms are designed to be therapeutically effective in treating or preventing diseases and disorders for which gabapentin is known to be beneficial.

Career Highlights

Balaji V Kadri is currently associated with Xenoport, Inc., where he continues to advance his research and development efforts. His work focuses on creating innovative solutions that enhance the efficacy of existing medications.

Collaborations

Throughout his career, Kadri has collaborated with esteemed colleagues, including Kenneth C Cundy and Srikonda Sastry. These partnerships have fostered a collaborative environment that encourages the exchange of ideas and expertise.

Conclusion

Balaji V Kadri's contributions to the field of pharmaceuticals through his patents and collaborations highlight his commitment to innovation. His work in developing sustained release oral dosage forms has the potential to improve patient outcomes significantly.